Paul Saftig Selected Research

Cathepsin D

1/2022	Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.
1/2022	Intravitreal gene therapy restores the autophagy-lysosomal pathway and attenuates retinal degeneration in cathepsin D-deficient mice.
1/2021	Rapid and Progressive Loss of Multiple Retinal Cell Types in Cathepsin D-Deficient Mice-An Animal Model of CLN10 Disease.
1/2020	Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40.
1/2020	Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis.
1/2019	Presynaptic Endosomal Cathepsin D Regulates the Biogenesis of GABAergic Synaptic Vesicles.
1/2017	Haplodeficiency of Cathepsin D does not affect cerebral amyloidosis and autophagy in APP/PS1 transgenic mice.
3/2013	Differences in expression patterns of cathepsin C/dipeptidyl peptidase I in normal, pathological and aged mouse central nervous system.
7/2010	CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis.
8/2008	Accumulation of bis(monoacylglycero)phosphate and gangliosides in mouse models of neuronal ceroid lipofuscinosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Saftig Research Topics

Disease

26	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 12/2003
12	Neoplasms (Cancer) 01/2022 - 03/2004
11	Inflammation (Inflammations) 01/2022 - 09/2006
10	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 01/2022 - 02/2007
8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 06/2006
7	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2019 - 07/2005
7	alpha-Mannosidosis 10/2017 - 09/2004
6	Parkinson Disease (Parkinson's Disease) 01/2022 - 02/2009
5	Amyloid Plaque 11/2021 - 02/2011
5	Gaucher Disease (Gaucher's Disease) 10/2016 - 11/2007
5	Bone Resorption 04/2013 - 09/2006
4	Synucleinopathies 01/2022 - 02/2009
4	Osteoporosis 05/2016 - 09/2008
4	Infections 01/2016 - 02/2006
4	Arthritis (Polyarthritis) 04/2013 - 02/2008
3	Prion Diseases (Transmissible Spongiform Encephalopathies) 11/2021 - 02/2015
3	Dementia (Dementias) 10/2016 - 01/2008
3	Fibrosis (Cirrhosis) 04/2015 - 06/2004
3	Atherosclerosis 12/2013 - 09/2008
2	Lymphopenia (Lymphocytopenia) 05/2022 - 07/2010
2	Retinal Degeneration 01/2022 - 01/2021
2	Hypertrophy 01/2022 - 05/2007
2	Neoplasm Metastasis (Metastasis) 01/2022 - 11/2016
2	Gliosis 10/2021 - 01/2021
2	Brain Diseases (Brain Disorder) 01/2018 - 12/2015
2	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 09/2016 - 02/2010
2	Atherosclerotic Plaque (Atheroma) 04/2015 - 09/2008
2	Seizures (Absence Seizure) 08/2013 - 07/2010
2	Obesity 04/2013 - 08/2007
2	Colitis 04/2013 - 08/2010
2	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 01/2012 - 12/2005
2	Atrophy 02/2011 - 02/2003
2	Mannosidase Deficiency Diseases (Mannosidosis) 01/2011 - 08/2006
2	Skin Diseases (Skin Disease) 07/2008 - 05/2004
2	Autoimmune Diseases (Autoimmune Disease) 02/2008 - 07/2004
2	Starvation 09/2004 - 07/2004

Drug/Important Bio-Agent (IBA)

27	Proteins (Proteins, Gene)FDA Link 10/2021 - 03/2003
18	Cathepsin DIBA 01/2022 - 02/2003
14	Peptide Hydrolases (Proteases)FDA Link 10/2021 - 06/2005
14	Amyloid (Amyloid Fibrils)IBA 01/2020 - 12/2003
13	EnzymesIBA 01/2022 - 12/2004
13	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2016 - 07/2004
12	Metalloproteases (Metalloproteinases)IBA 01/2022 - 07/2006
12	Cathepsin KIBA 05/2016 - 06/2004
8	DisintegrinsIBA 01/2020 - 09/2006
7	Peptides (Polypeptides)IBA 05/2022 - 10/2006
7	Lysosomal Membrane ProteinsIBA 10/2020 - 03/2003
7	AcidsIBA 12/2017 - 09/2004
7	alpha-Mannosidase (LAMAN)IBA 10/2017 - 09/2004
6	Glucosylceramidase (Glucocerebrosidase)IBA 01/2022 - 11/2007
6	Cysteine Proteases (Cysteine Protease)IBA 02/2015 - 09/2006
5	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 05/2022 - 01/2020
5	Mannose (D-Mannose)IBA 01/2022 - 09/2004
5	Retinaldehyde (Retinal)IBA 01/2022 - 02/2003
4	Cathepsin LIBA 05/2022 - 10/2011
4	SynucleinsIBA 01/2022 - 06/2011
4	Prion ProteinsIBA 01/2022 - 02/2015
4	Pharmaceutical PreparationsIBA 01/2022 - 05/2011
4	LigandsIBA 11/2021 - 03/2004
4	LipidsIBA 01/2021 - 12/2005
4	Aspartic Acid ProteasesIBA 01/2021 - 12/2003
4	CeroidIBA 01/2020 - 02/2007
4	CholesterolIBA 08/2014 - 12/2005
4	Amyloid beta-PeptidesIBA 04/2012 - 12/2004
3	Cathepsin BIBA 01/2022 - 01/2020
3	SaposinsIBA 01/2022 - 01/2020
3	PrionsIBA 11/2021 - 01/2015
3	HydrolasesIBA 01/2017 - 11/2015
3	OligosaccharidesIBA 11/2015 - 09/2004
3	CytokinesIBA 02/2011 - 07/2008
2	Lysosomal-Associated Membrane Protein 2IBA 05/2022 - 01/2020
2	IGF Type 2 Receptor (Insulin-Like-Growth-Factor II Receptor)IBA 01/2022 - 11/2007
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 02/2011
2	Lysosomal-Associated Membrane Protein 1IBA 01/2022 - 01/2020
2	Phosphates (Orthophosphate)IBA 01/2022 - 01/2020
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 02/2008
2	Amino Acids FDA Link 01/2022 - 07/2004
2	Amyloid beta-Protein Precursor (Amyloid Protein Precursor)IBA 01/2022 - 12/2009
2	Protein AggregatesIBA 10/2021 - 01/2020
2	lysosomal proteinsIBA 01/2021 - 07/2008
2	ProgranulinsIBA 10/2020 - 01/2017
2	LipofuscinIBA 01/2020 - 09/2007
2	Lysergic Acid Diethylamide (LSD)IBA 01/2020 - 01/2019
2	GlycosaminoglycansIBA 12/2018 - 11/2009
2	alpha-SynucleinIBA 10/2016 - 02/2009
2	TetraspaninsIBA 01/2016 - 09/2013
2	Cathepsin FIBA 02/2015 - 04/2013
2	Protein Isoforms (Isoforms)IBA 01/2015 - 11/2005
2	IgE Receptors (Fc epsilon RI)IBA 09/2013 - 12/2006
2	Presenilin-1IBA 04/2012 - 11/2004
2	GangliosidesIBA 01/2011 - 08/2008
2	Apolipoproteins E (ApoE)IBA 03/2010 - 09/2008
2	Virulence Factors (Pathogenicity Factors)IBA 01/2010 - 02/2006
2	Cadherins (E-Cadherin)IBA 07/2008 - 05/2007
1	SelectinsIBA 05/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2022
1	6-carboxyfluorescein (carboxyfluorescein)IBA 05/2022
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 05/2022

Therapy/Procedure

7	Enzyme Replacement Therapy 01/2022 - 09/2004
6	Therapeutics 01/2022 - 07/2006